ReviewJTO clinical and research reports2026
First-Line Platinum-Based Chemotherapy with Novel Systemic Agents for Unresectable or Metastatic Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis.
Review in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: preliminary results of a phase II trial with biomarker analyses.Journal for immunotherapy of cancer · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thymic epithelial tumors, including thymomas and thymic carcinomas (TC), are rare thoracic malignancies with poor prognosis in advanced stages. Platinum-based chemotherapy (CT) remains the first-line standard with limited efficacy. Novel systemic therapies, such as immune checkpoint inhibitors (ICIs) and antiangiogenic agents, have exhibited promise in refractory disease. Methods: A systematic search of PubMed, EMBASE, and Cochrane was performed for studies including patients with unresectable, recurrent, or metastatic thymic epithelial tumors treated with platinum-based CT combined with ICIs or antiangiogenic agents. Meta-analyses were conducted using a random-effects model, with heterogeneity assessed through the Results: Nine studies encompassing 208 patients were included, of which 93.7% had TC. The data set comprised five phase II trials and four retrospective cohorts. The pooled 12-month overall survival rate was 96.08% (95% confidence interval [CI]: 84.80-99.08), and 12-month progression-free survival was 56.68% (95% CI: 45.82-70.44). The median duration of response and median progression-free survival were 11.96 (95% CI: 6.32-22.64) months and 16.22 (95% CI: 10.30-25.52) months, respectively, with a pooled objective response rate of 57.69% (95% CI: 43.99-70.3). The objective response rate was 68.50% for antiangiogenic and 51.19% for ICIs combinations. Any-grade treatment-related adverse events occurred in 88.65%, grade 3 or higher in 30.22%, and grade 3 or higher immune-related adverse events in 11.62%, with treatment discontinuation in 13.55%. Conclusion: Platinum-based CT combined with ICIs or antiangiogenic agents exhibits promising efficacy and manageable toxicity, particularly in TC. Evidence in thymomas remains limited, and severe immune-related toxicity warrants caution. Randomized trials are needed for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.